John Santini

[Vergent Bioscience @VergentBio]

Vergent Bioscience names Adam Gridley President & CEO. John Santini, PhD, moves to CTO to lead platform expansion as we advance a Phase 3 study evaluating abenacianine for tumor visualization during lung cancer surgery.

Read more: https://t.co/9aPfaHSsgL

#Leadership

[John Santini @jsantini1]

The VISUALIZE study is an exciting next step for VGT-309 and we look forward to further evaluating its utility in lung cancer surgery.

[Vergent Bioscience @VergentBio]

#NEWS: The first patients have been enrolled in our Phase 2 multi-center VISUALIZE study! The study will assess the potential of our tumor-targeted fluorescent imaging agent, VGT-309, to improve visibility of tumors during lung cancer surgery. Read more: https://t.co/vOUCOP4yMt
#clinicaltrials #medtwitter #meded

[John Santini @jsantini1]

It was great to have so many attendees at Dr. Wright's presentation of phase 2 VGT-309 study data earlier today. #WCLC23 @IASLC

[Vergent Bioscience @VergentBio]

Today we presented new data at the @IASLC 2023 World Conference on #LungCancer providing compelling evidence that VGT-309 increases the potential that surgeons can identify all tumor tissue during minimally invasive and robotic surgery. #WLCL23 Read more: https://t.co/fSYVIUkWqx

[John Santini @jsantini1]

We are grateful to the NCI and the team at Penn for their support of our Phase 2 trial of VGT-309 in lung cancer.

[Vergent Bioscience @VergentBio]

We’ve been awarded a Small Business #Innovation Research grant from @NIH.

This will support our study of targeted fluorescent imaging agent to improve #tumorvisualization.

Read the announcement: https://t.co/eNPluLal6i

[John Santini @jsantini1]

Previous clinical studies have validated the potential of VGT-309, and these additional funds will enable us to efficiently advance our current and future clinical trials in #LungCancer.

[Vergent Bioscience @VergentBio]

Vergent Bioscience Secures $21.5 Million Series B Financing to Advance Clinical Development of Tumor-Targeted Fluorescent Imaging Agent VGT-309.

Read the full media release: https://t.co/TTwCUwzeVs

#innovation #tumorvisualization